Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile for Moderate COVID-19 and Early CRS
NCT04540120Phase 2Terminated
- Sponsor
- Olatec Therapeutics LLC
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of dapansutrile in coronavirus disease 2019 (COVID-19), cytokine release syndrome (CRS), sponsored by Olatec Therapeutics LLC. Started Sep 2020; status: terminated.
02
Drugs
dapansutrile
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04540120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540120.